Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American College of Cardiology Meeting In Brief: Warner-Lambert's Accupril

Executive Summary

Warner-Lambert's Accupril: Six-month treatment with Accupril (quinapril) improves endothelial function, an early marker of coronary atherosclerosis, in patients with established coronary disease and abnormal responses to acetylcholine, according to results from the Trial on Reversing Endothelial Dysfunction (TREND), presented March 24. In 129 patients undergoing PTCA randomized to 40 mg quinapril daily or placebo, the mean percent change in acetylcholine-induced diameter of the target coronary segment at six months was a 12.1% increase for quinapril and a .8% decrease for placebo (p=.002) in patients with 10-4 m diameters...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel